Strategic partnership Hemotek has a history of collaboration with Baylor and is pursuing FDA approval for Ox66, indicating a potential path for partner-driven co-development, licensing, or distribution arrangements with large medical institutions or pharma manufacturers seeking oxygen therapeutics.

Clinical readiness Ox66 is in the market with multiple commercial customers while advancing toward FDA approval, presenting an opportunity to engage early adopters and contract manufacturers for scale-up, regulatory guidance, and pilot studies to accelerate market access.

Regulatory upside The product’s ongoing regulatory journey suggests demand for advisory, compliance, and quality systems support, as well as potential channel partnerships with healthcare distributors seeking to align with innovative oxygenation therapies.

Health tech stack Hemotek leverages a modern tech stack and cloud infrastructure which could enable integration services, data collaboration, and digital health partnerships for monitoring, reporting, or telemedicine-enabled deployment of Ox66 in clinical settings.

Market potential With a revenue range in the low to mid millions and a unique non-gaseous oxygen product, there isOpportunity to target pharmaceutical manufacturers, hospitals, and labs requiring oxygen delivery solutions, as well as licensing opportunities with larger diagnostics players seeking portfolio diversification.